Acurx Pharmaceuticals Files Amendment to S-1 Registration Statement

TL;DR

<b>Acurx Pharmaceuticals, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to comply with securities regulations.</b>

AI Summary

Acurx Pharmaceuticals, Inc. (ACXP) filed a Amended IPO Registration (S-1/A) with the SEC on March 29, 2024. Acurx Pharmaceuticals, Inc. filed an amendment (S-1/A) to its registration statement on March 29, 2024. The filing is related to the Securities Act of 1933, with registration number 333-278028. The company's principal executive offices are located at 259 Liberty Avenue, Staten Island, New York 10305. David P. Luci is listed as President and Chief Executive Officer. The filing indicates the company is a smaller reporting company and an emerging growth company.

Why It Matters

For investors and stakeholders tracking Acurx Pharmaceuticals, Inc., this filing contains several important signals. This amendment suggests Acurx Pharmaceuticals is actively working towards a public offering or other securities-related transactions, requiring updated regulatory disclosures. The filing provides essential information for potential investors and regulatory bodies regarding the company's structure, leadership, and compliance status.

Risk Assessment

Risk Level: low — Acurx Pharmaceuticals, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural step and does not inherently indicate significant new risks or positive developments.

Analyst Insight

Monitor future filings for details on the proposed offering, financial performance, and strategic developments of Acurx Pharmaceuticals.

Key Numbers

• 333-278028 — SEC File Number (Registration Number)
• 2024-03-29 — Filing Date (Amendment No. 1 to FORM S-1)
• 1231 — Fiscal Year End (Company Fiscal Year End)
• DE — State of Incorporation (Jurisdiction of Incorporation)

Key Players & Entities

• Acurx Pharmaceuticals, Inc. (company) — Registrant
• 0001736243 (company) — Central Index Key
• 2834 (company) — Primary Standard Industrial Classification Code Number
• 82-3733567 (company) — I.R.S. Employer Identification Number
• 259 Liberty Avenue Staten Island, New York 10305 (company) — Business Address
• David P. Luci (person) — President and Chief Executive Officer
• 333-278028 (regulator) — SEC File Number
• March 29, 2024 (date) — Filing Date

FAQ

Industry Context

Acurx Pharmaceuticals operates within the pharmaceutical preparations industry, focusing on the development and commercialization of pharmaceutical products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offered to the public in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed disclosures on the company's business, financials, and risk factors.
2. Track subsequent SEC filings for updates on Acurx Pharmaceuticals' offering status and corporate actions.
3. Research the company's product pipeline and market strategy to assess its growth potential.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating updates or corrections to the initial disclosures.

Key Financial Figures

• $2.08 — our common stock on March 26, 2024 was $2.08 per share. The final public offering pr
• $2.0 million — ons payable by us will be approximately $2.0 million and the total proceeds to us, before ex
• $26.7 million — before expenses, will be approximately $26.7 million. Neither the Securities and Exchange
• $17.0 million — ng an aggregate offering price of up to $17.0 million. Under the Sales Agreement, the sales a
• $3.76 — Program at a weighted-average price of $3.76 per share, raising $2.6 million of gros
• $2.6 million — erage price of $3.76 per share, raising $2.6 million of gross proceeds and net proceeds of $
• $2.4 m — n of gross proceeds and net proceeds of $2.4 million, after deducting commissions to t
• $14.4 million — d expenses. There remains approximately $14.4 million available for future sales of shares of
• $3.00 — of common stock at an offering price of $3.00 per share and an aggregate of 731,482 p
• $2.9999 — of common stock at an offering price of $2.9999 per pre-funded warrant. The pre-funded
• $0.0001 — 2023 Investor have an exercise price of $0.0001 and were immediately exercisable. As of
• $4.0 million — Registered Offering were approximately $4.0 million and net proceeds after deducting the pl
• $3.5 million — penses payable by us were approximately $3.5 million. The securities were offered by us purs
• $3.26 — of common stock at an exercise price of $3.26 per share and Series D Warrants exercis
• $1.07 b — total annual gross revenues of at least $1.07 billion, (3) the date on which we are dee

Filing Documents

• tm248533d2_s1a.htm (S-1/A) — 403KB
• tm248533d2_ex5-1.htm (EX-5.1) — 11KB
• tm248533d2_ex23-1.htm (EX-23.1) — 2KB
• tm248533d1_s1sp1img001.jpg (GRAPHIC) — 12KB
• tm248533d1_s1img01.jpg (GRAPHIC) — 9KB
• tm248533d2_ex5-1img001.jpg (GRAPHIC) — 2KB
• tm248533d2_ex5-1img002.jpg (GRAPHIC) — 1KB
• 0001104659-24-041187.txt (&nbsp;) — 451KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING 11

USE OF PROCEEDS

USE OF PROCEEDS 13 MARKET FOR COMMON STOCK AND DIVIDEND POLICY 14 CAPITALIZATION 15

DILUTION

DILUTION 17 DESCRIPTION OF THE SECURITIES WE ARE OFFERING 18 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO HOLDERS OF COMMON STOCK 21

UNDERWRITING

UNDERWRITING 25 LEGAL MATTERS 28 EXPERTS 28 WHERE YOU CAN FIND MORE INFORMATION 28 INCORPORATION OF DOCUMENTS BY REFERENCE 29 i ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated by reference herein or any amendment thereto. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the heading &ldquo;Where You Can Find More Information.&rdquo; We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus, the documents incorporated by reference herein or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The information contained in this prospectus, the documents incorporated by reference herein or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, resul

View Full Filing

View this S-1/A filing on SEC EDGAR